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PENGARUH CROSPOVIDONE KE ATAS BIOKEPEROLEHAN ORAL DRUG 
DAN TOKSIN MODEL 
 
ABSTRAK 
 
Kajian ini dijalankan untuk menyiasat potensi crospovidone dalam pencegahan toksisiti 
aflatoxin B1 serta kebolehannya untuk meningkatkan biokeperolehan oral drug yang 
mempunyai keterlarutan rendah dalam air, iaitu ibuprofen. Pada peringkat awal kajian 
ini, satu kaedah kromatografi cecair prestasi tinggi yang ringkas, spesifik dan sensitive 
telah berjaya dibangunkan untuk menentukan kepekatan aflatoxin B1 dalam plasma. 
Kaedah ini mempunyai kejituan dan ketepatan yang baik bagi julat kepekatan dari 0.1 
ng/ml ke 50.0 ng/ml. 
 
Pelbagai faktor yang mempengaruhi penjerapan aflatoxin B1 terhadap crospovidone, 
seperti kepekatan crospovidone, masa hidrasi, masa reaksi, pH and nisbah drug 
kepada polimer telah dikaji untuk mendapatkan keadaan optimum bagi penyediaan 
formulasi aflatoxin B1-crospovidone.  Seterusnya, satu formulasi aflatoxin B1-
crospovidone dengan nisbah drug kepada polimer 1:200 yang disediakan dalam 
keadaan optimum telah diberikan kepada tikus Sprague-Dawley dalam satu kajian in 
vivo. Kajian biokeperolehan ini telah dijalankan mengikut rekabentuk perbandingan 
selari untuk menyelidik biokeperolehan oral aflatoxin B1 dalam bentuk larutan akueus 
aflatoxin B1 dan formulasi aflatoxin B1-crospovidone. Walau bagaimanapun, profil 
plasma bagi kedua-dua formulasi didapati tidak menunjukkan perbezaan yang ketara. 
Ini menunjukkan bahawa crospovidone tidak mengubah biokeperolehan aflatoxin B1 
dengan signifikan. 
 
Selain itu, kebolehan crospovidone untuk meningkatkan biokeperolehan oral ibuprofen 
juga telah dijalankan dengan menggunakan tikus. Kajian in vivo ini telah dijalankan 
 xxi 
mengikut rekabentuk bersilang dua-hala untuk membanding biokeperolehan oral bagi 
formulasi ibuprofen-crospovidone dalam larutan penimbal fosfat pH 2.4 dengan 
suspensi ibuprofen dalam larutan penimbal fosfat pH 2.4. Kajian tersebut menunjukkan 
bahawa formulasi ibuprofen-crospovidone dapat meningkatkan biokeperolehan oral 
ibuprofen sebanyak kira-kira 5 kali berbanding dengan suspensi ibuprofen. 
Kesimpulannya, crospovidone didapati dapat membantu meningkatkan biokeperolehan 
oral drug yang  mempunyai keterlarutan rendah dalam air seperti ibuprofen.  
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INFLUENCE OF CROSPOVIDONE ON THE ORAL BIOAVAILABILITY OF A 
MODEL DRUG AND TOXIN 
 
ABSTRACT 
 
The present study was conducted to evaluate the potential of crospovidone in 
preventing aflatoxin B1 toxicity as well as its ability to enhance the oral bioavailability of 
a poorly water-soluble drug, namely ibuprofen. In the first part of the study, a simple, 
specific and sensitive high performance liquid chromatographic method was 
successfully developed for the analysis of aflatoxin B1 in plasma. The method has good 
precision and accuracy over concentrations ranging from 0.1 ng/ml to 50.0 ng/ml. 
 
Various factors affecting the adsorption of aflatoxin B1 to crospovidone, such as 
concentration of crospovidone, hydration time, contact time, pH and drug to polymer 
ratio were investigated to obtain the optimum conditions for preparation of aflatoxin B1-
crospovidone formulation.  Subsequently, an aflatoxin B1-crospovidone formulation with 
a drug to polymer ratio of 1:200 was administered to Sprague-Dawley rats in an in vivo 
study. This comparative bioavailability study was conducted according to a parallel 
study design to evaluate the oral bioavailability of aflatoxin B1 administered as an 
aqueous solution and aflatoxin B1-crospovidone formulation. The plasma profiles of the 
two preparations were closely similar indicating that crospovidone did not significantly 
alter the oral bioavailability of aflatoxin B1. 
 
The ability of crospovidone for enhancing oral bioavailability of ibuprofen was also 
evaluated in rats. The in vivo evaluation was conducted according to a crossover study 
design to compare the oral bioavailability of ibuprofen-crospovidone formulation in 
phosphate buffer pH 2.4 and ibuprofen suspension in phosphate buffer pH 2.4. The 
study showed that the ibuprofen-crospovidone formulation could increase the oral 
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availability of ibuprofen by approximately 5.0 times compared to the ibuprofen 
suspension. In conclusion, crospovidone was found to be useful in enhancing the oral 
bioavailability of a pooly water-soluble drug such as ibuprofen.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Bioavailability and absorption of drugs 
1.1.1 Introduction 
The terms oral absorption and oral bioavailability are widely used in the 
pharmacokinetic and biopharmaceutic literature. They have been treated either 
identically or differently in several widely cited books and created confusion in 
publications (Chiou, 2001). Oral absorption is defined as the process by which a drug 
proceeds from the site of administration (mouth) to the site of measurement (systemic 
circulation) within the body (Rowland and Tozer, 1980) whereas oral bioavailability 
refers to the rate and extent of absorption of a drug from its dosage form into the 
systemic circulation (Wagner, 1975). 
 
1.1.2 Oral drug absorption 
There are many routes of drug administration such as oral, intravenous, transdermal, 
intramuscular, subcutaneous, buccal, nasal, rectal and inhalation. Of these, the oral 
route remains the most preferred because it is the simplest, most convenient and 
safest means of drug administration (York, 2002). However, there are some 
disadvantages associated with oral dosing. One of the disadvantages is the 
interindividual and intraindividual variations in both the rate and extent of oral 
absorption (Lin et al., 1999). Other disadvantages, include poor stability of some drugs 
in the low pH of the gastric juices, first-pass metabolism effect of the liver and difficulty 
in swallowing the dosage form (Barich et al., 2005). 
 
Gastrointestinal tract is a muscular tube of approximately 6 m in length stretching from 
the mouth to the anus. The four main anatomical areas are the oesophagus, stomach, 
small intestine and large intestine. The mouth is the point of entry for oral drugs. It is 
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linked to the stomach via the oesophagus (Ashford, 2002a). In the stomach, the 
ingested solids are reduced to chyme by the action of acid and enzymatic digestion 
(Washington et al., 2001a).  
 
The next part of the gastrointestinal tract to be encountered by pharmaceuticals is the 
small intestine, which enables efficient absorption of nutrients, fluids, electrolytes, and 
drugs, as well as the simultaneous exclusion of antigenic or toxic inflammatory 
substances (Knutson et al., 2000). The large intestine is the final part of the 
gastrointestinal tract. It is concerned primarily with the absorption of water and 
secretion of mucus to aid the unabsorbed intestinal contents to slide down the 
intestines (Florence and Attwood, 1988a).  
 
For a drug molecule to be orally bioavailable, it has to traverse the epithelial layer of 
the gastrointestinal tract. It needs to remain in solution in order to be absorbed. The 
drug then needs to diffuse across the mucous layer, across the unstirred water layer, 
and subsequently across the gastrointestinal membrane. After passing through this 
cellular barrier the drug encounters the liver before it reaches the systemic circulation 
(Ashford, 2002a). Moreover, the drug must overcome the chemical barrier which 
consists of metabolizing enzymes that can degrade it. At the same time, it must have 
optimal physiochemical properties for its permeation across the biological barriers 
(Calcagno and Siahaan, 2005).  
 
Thus, there are many factors that can influence the rate and extent of drug absorption 
and these include physiological, physicochemical and formulation factors and they are 
briefly discussed in the following sections. 
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1.1.3 Physiological factors influencing oral drug absorption 
1.1.3(a) Membrane permeability 
The gastrointestinal membrane separates the lumen of the stomach and intestines 
from the systemic circulation. It is the main barrier to the absorption of drugs from the 
gastrointestinal tract. The membrane is semipermeable in nature. It allows the passage 
of lipid-soluble molecules across it and the passage of water and small hydrophilic 
molecules through its numerous aqueous pores. Additionally, there are some 
transporter proteins that exist in the membrane which transport materials back and 
forth across it (Ashford, 2002a).  
 
As most drugs are weak electrolytes, it is expected that the unionised form of either 
acidic or basic drugs, being the lipid soluble species, will diffuse across the 
gastrointestinal membrane while the ionised forms will be rejected. This is the basis of 
the pH-partition hypothesis in which drug absorption and solute transport across 
membrane is pH dependent (Florence and Attwood, 1988a). However, absorption is a 
dynamic process involving dissolution, ionization, partition and blood flow, and 
consequently the correlation of pH-partition predictions with experiments is often poor 
(Washington et al., 2001b).  
 
1.1.3(b) Membrane transport mechanism 
There are two main mechanisms of drug transport across the gastrointestinal 
membrane, the transcellular and paracellular. The transcellular or across the cell 
pathway is further divided into simple passive diffusion, carrier-mediated transport and 
endocytosis.  
 
Passive diffusion is the major route of transport for relatively small lipophillic molecules 
encompassing many drugs. Passive diffusion is a term used to characterize the 
movement of drug molecules down a concentration gradient without cellular 
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expenditure of energy. This process is neither saturable nor inhibited by other 
molecules (Bourne et al., 1986). The rate of transport is determined by the 
physicochemical properties of the drug, the nature of the membrane and the 
concentration gradient of the drug across the membrane (Ashford, 2002a). The drug 
transport rate of passive diffusion increases in parallel with drug lipophilicity and 
inversely with the square root of molecular size (Terasaki and Ohtsuki, 2005). 
 
There are certain compounds that are absorbed transcellularly by a carrier-mediated 
transport mechanism, of which there are two main types, active transport and facilitated 
diffusion. In active transport, materials can be transported across membrane against a 
concentration gradient. This process requires metabolic energy and it can be inhibited 
by inhibitors of cellular energy metabolism (Bourne et al., 1986).  
 
There are a large number of carrier-mediated active transport systems in the small 
intestine such as the peptide transporters, nucleoside transporters, sugar transporters, 
bile acid transporters, organic anion transporters and vitamin transporters. Many 
nutrients, such as amino acids, sugars, electrolytes, vitamins and bile salts are actively 
transported (Ashford, 2002a). The peptide-like drugs, such as the β-lactam antibiotics, 
angiotensin-converting enzyme inhibitors, and bestatin, rely on the intestinal dipeptide 
transporter PepT1 for their efficient absorption (Lee, 2000). 
 
On the other hand, facilitated diffusion differs from active transport in that it cannot 
transport a substance against a concentration gradient of that substance. Therefore, 
facilitated diffusion does not require an energy input but does require a concentration 
gradient for its driving force (Ashford, 2002a). Another type of transcellular transport is 
by endocytosis. Endocytosis is the uptake of extracellular material, exogenous 
molecules, or macromolecules into a cell by invagination of the plasma membrane and 
vesicle formation (Ritschel and Kearns, 2004a).  
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The paracellular pathway is the transport of materials in the aqueous pores between 
the cells rather than across them. The cells are joined together via closely fitting tight 
junctions on their apical side. The paracellular route of absorption is important for the 
transport of ions such as calcium and for the transport of sugars, amino acids and 
peptides at concentrations above the capacity of their carriers. Small hydrophilic and 
charged drugs also cross the gastrointestinal epithelium via the paracellular pathway. 
The molecular weight cut-off for the paracellular route is usually considered to be 200 
Da (Ashford, 2002a). 
 
1.1.3(c) Gastrointestinal pH 
The pH of fluids along the gastrointestinal tract varies considerably. The gastric juice is 
highly acidic, with a pH within the range of 1 – 3.5 in the fasted state. However, the 
intestinal pH values are higher than gastric pH values with pH ranges between 4.4 – 
7.4 (Ashford, 2002a). Many drugs are ionisable within the physiological pH range 
(Ozturk et al., 1988), which impacts their aqueous solubility (TenHoor et al., 1991). For 
drugs absorbed by passive diffusion, those exhibiting low aqueous solubility tend to 
have a slower oral absorption rate than those exhibiting high aqueous solubility (Kwan 
et al., 1986). 
 
The pH of the gastrointestinal tract may also affect the rate of dissolution of a drug from 
a formulation, or drug stability. The effect of pH on drug stability can be exemplified by 
the acid-labile penicillin antibiotics and certain polypeptides such as insulin (Bourne et 
al., 1986).  The result of this instability is incomplete and poor bioavailability, as only a 
fraction of the administered dose reaches the systemic circulation in the form of intact 
drug (Ashford, 2002a). 
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1.1.3(d) Gastric emptying rate 
Stomach acts as a reservoir, and regulates the passage of materials to the duodenum 
and small intestine where absorption takes place. As the absorptive capacity of the 
small intestine is far larger than that of the stomach, the gastric emptying rate may 
profoundly influence the rate and extent of absorption (Bourne et al., 1986, Ritschel 
and Kearns, 2004b). Gastric emptying of pharmaceuticals is highly variable and is 
dependent on the dosage form and the fed or fasted state of the stomach. Normal 
gastric residence time usually ranges between 5 minutes and 2 hours (Ashford, 2002a).  
 
A number of factors can influence the gastric emptying rate. These include the amount 
and composition of food (Palin et al., 1982), viscosity of gastrointestinal content (Smart 
and Kellaway, 1989) and drug given concomitantly (Levy et al., 1972). Other 
physiological factors such as position of body and exercise were reported to have a 
limited effect. However, penicillins are unstable in acid and decompose if stomach 
emptying is delayed. Other drugs, such as aspirin, may irritate the gastric mucosa 
during prolonged contact (Shargel and Yu, 1993).  
 
1.1.3(e) Intestinal transit and motility 
The intestinal transit time is an important factor in determining efficient drug absorption 
because it determines the residence time of the drug in the absorption site (Kimura and 
Higaki, 2002). Mean small intestinal transit time has been found consistent, between 3 
and 4 hours, and is independent of fed or fasted state conditions (Yu et al., 1996). 
However, some drugs (Greiff and Rowbothan, 1994) and drug excipients (Basit et al., 
2002) have been shown to influence the extent of drug absorption by accelerating the 
intestinal transit. 
 
On the contrary, the colonic transit of pharmaceuticals is long and variable. It can vary 
from anything between 2 and 48 hours (Ashford, 2002a). The human colon has a lower 
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absorption capacity than the small intestine, but its contents remain in the human colon 
for much longer. The long colonic residence time provides a significant opportunity for 
the slow absorption of drugs that are either targeted specifically or those remaining 
unabsorbed after reaching the colon (Edwards, 1997).  
 
1.1.3(f) Perfusion of the gastrointestinal tract 
The blood flow to the gastrointestinal tract is important in carrying the absorbed drug to 
the systemic circulation. A large network of capillaries and lymphatic vessels perfuse 
the small intestine. The splanchnic circulation receives about 28% of the cardiac output 
(Shargel and Yu, 1993). Blood flow to the gastrointestinal tract and liver increases 
shortly after a meal, thereby increases hepatic drug delivery and reduces presystemic 
metabolism (Ashford, 2002a). Thus, for drugs exhibiting a large first-pass effect such 
as propanolol, concomitant intake with food may increase drug bioavailability due to 
reduced presystemic metabolism (Liedholm et al., 1990). Besides, gastrointestinal 
blood supply may be reduced in certain disease states such as congestive heart failure 
(Carlton et al., 1996). 
 
The majority of orally administered drugs gain access to the systemic circulation by 
absorption into the portal blood. However, some lipophilic compounds are transported 
via the intestinal lymphatics to the systemic circulation (Porter and Charman, 1997). 
The lymphatics are important in the absorption of dietary lipids, fat soluble vitamins (A, 
D, E and K) and many lipophilic drugs such as cyclosporine (Ueda et al., 1983). 
Absorption of drugs through the lymphatic system bypasses the first-pass effect due to 
liver metabolism (Shargel and Yu, 1993).  
 
1.1.3(g) Food-drug interaction 
The presence of food in the gastrointestinal tract can influence the rate and extent of 
absorption of the drug. Food can influence drug absorption through physicochemical 
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and physiological interactions (Fleisher et al., 1999). One of the effects is the 
complexation of drugs with components in the diet, forming insoluble complexes. The 
fraction of the administered dose that becomes complexed is unavailable for absorption 
(Ashford, 2002a). One example is tetracycline which forms non-absorbable complexes 
with calcium (Kakemi et al., 1968).  
 
The presence of food also influences drug absorption by altering the intestinal pH and 
solubility of drugs, delaying gastric emptying, stimulating gastrointestinal secretions, 
creating competition for specialized absorption mechanisms and increasing the 
viscosity of gastrointestinal contents (Ashford, 2002a). Food-drug interactions may 
caused reduced, delayed, increased or accelerated absorption (Fleisher et al., 1999). 
 
1.1.3(h) First-pass metabolism 
The metabolism of drugs before entering the systemic circulation is referred to as first-
pass metabolism (Lin et al., 1999). Metabolism of drugs administered orally may occur 
either in the gut wall or in the liver (Washington et al., 2001c). All drugs that are 
absorbed from the stomach, small intestine and upper colon pass into the hepatic 
portal system and are presented to the liver before reaching the systemic circulation. 
Hence, an oral dose of drug could be completely absorbed but incompletely available 
to the systemic circulation due to first-pass metabolism by enzymes in the gut wall or 
liver (Ashford, 2002a).  
 
The cytochrome P450 (CYP) enzymes are a large family of enzymes expressed 
predominantly in the liver, but are found in many other tissues, and play a role in the 
metabolic clearance of many drugs (Humphreys, 2005). Among them, CYP3A4 is the 
most important enzyme because it is found in the greatest quantity and it has the 
broadest range of known substrate. For example, cyclosporine A is susceptible to 
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extensive gut and liver metabolism by CYP3A4, resulting in a significant reduction in its 
bioavailability (Wu et al., 1995). 
 
1.1.3(i) The intestinal drug efflux 
There are countertransport efflux proteins in the plasma membrane that actively 
remove a wide range of structurally and functionally distinct molecules back into the 
lumen of the gastrointestinal tract after they have been absorbed (Zhang and Morris, 
2005). One of these proteins is P-glycoprotein. P-glycoprotein is a transmembrane 
efflux protein found in tumour cells. Besides, it is detected in the adrenal glands and on 
the apical side of the epithelial cells in the liver, kidney, pancreas and intestine 
(Thiebaut et al., 1987).  
 
Since P-glycoprotein is expressed in high levels on the apical surface of columnar cells 
in the jejunum, it may affect the absorption and bioavailability of drugs (Ashford, 2002a). 
There are a number of drugs with wide structural diversity such as cyclosporine A, 
vinca alkaloids, digoxin, erythromycin, antibiotics and cimetidine that are susceptible to 
efflux from the intestine via P-glycoprotein (Washington et al., 2001c). Such efflux may 
have a detrimental effect on drug bioavailability. 
 
1.1.4 Physicochemical factors 
1.1.4(a) Lipophilicity 
Biological membranes are lipoidal in nature and are more permeable to lipid soluble 
substances. Therefore, transport across these membranes depends, in part, on the 
lipid solubility of the diffusing species (Kwan et al., 1986). The octanol/water partition 
coefficients (log P) is widely used as an indication of the lipid solubility of a drug, and 
whether that drug is liable to be transported across membranes (Ashford, 2002b).  
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Drug absorption usually increases as the lipophilicity rises. This has been shown with a 
series of β-blockers (Taylor et al., 1985). However, the rate of passive diffusion across 
the biological membrane will increase exponentially with increasing lipophilicity and 
then level off at higher lipophilicity due to a decrease in water solubility (Hu, 2005). 
   
1.1.4(b) Stability 
Chemical stability of a drug in the gastrointestinal fluids is very important. If the drug is 
unstable in the gastrointestinal fluids, the amount of drug that is available for absorption 
will be reduced and its bioavailability also reduced. Besides, chemical degradation 
products may adversely affect the physicochemical properties of a formulated product 
and may even be toxic (Barich et al., 2005). Chemical instability is often a function of 
pH. Therefore, stability in acid is a concern particularly for drugs intended for oral 
administration (Kwan et al., 1986). The antibiotic, erythromycin (Cachet et al., 1989) 
and proton pump inhibitor, omeprazole (Türkoğlu et al., 2004) degrade rapidly at acidic 
pH values and therefore are formulated as enteric-coated dosage forms to ensure good 
bioavailability (Ashford, 2002a). 
 
1.1.4(c) Solubility 
Drug absorption requires that molecules be in solution at the absorption site and 
dissolution depends in part on the solubility of the drug substance in the surrounding 
medium (Kwan et al., 1986). Therefore, the lack in the ability of a drug to go into 
solution is sometimes a more important limitation to its overall rate of absorption than 
its ability to permeate the intestinal mucosa (Hörter and Dressman, 2001). Solubility of 
drugs that are weak electrolytes is affected by pH due to the effects of pH on drug 
ionisation. Generally, ionised drugs tend to exhibit far greater aqueous solubility than 
the unionised counterpart (Martinez and Amidon, 2002).  
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The solubility of weakly acidic drugs increases with pH while the solubility of weak 
bases decreases with increasing pH. Hence, the solubility of a drug may change when 
it moves down the gastrointestinal tract from the stomach to the intestine (Ashford, 
2002b). For instance, the antifungal drug ketoconazole, a weak base, is particularly 
sensitive to gastric pH.  It has been reported that an increase in gastric pH produced by 
cimetidine or antacids decreases the absorption of ketoconazole (Männistö et al., 
1982). 
 
1.1.4(d) Particle size 
Particle size is another parameter that influences drug dissolution, and in turn, drug 
absorption. Small particles with greater surface area dissolve more rapidly than larger 
particles, even though both have the same intrinsic solubility (Kwan et al., 1986). 
Therefore, particle size reduction is likely to result in increased bioavailability, provided 
the absorption of the drug is dissolution-rate limited (Ashford, 2002b). For example, the 
absorption of a poorly water soluble drug, griseofulvin, was doubled when the particle 
size was decreased from about 10 µm to 2.7 µm (Atkinson et al., 1962, Chattopadhyay 
and Gupta, 2001). 
 
1.1.4(e) Dissociation constant 
The dissociation constant (pKa) of a drug and the pH at the absorption site often 
influence the absorption characteristics of a drug throughout the gastrointestinal tract 
(Ashford, 2002b). According to the pH-partition hypothesis of drug absorption, the 
unionised species of acidic or basic compounds in solution penetrates lipoidal 
membranes of the gastrointestinal tract more efficiently than the ionised species. 
Therefore, the rate of absorption of a drug is directly related to the concentration of its 
unionised species at the absorption site (Kwan et al., 1986). This means that a weakly 
acidic drug is more likely to be absorbed from the stomach where it is unionised, and a 
weakly basic drug from the intestine where it is predominantly unionised. 
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However, there are limitations of this hypothesis. This hypothesis is valid only if factors 
such as surface area and pH of stomach and small intestine are constant. In fact, the 
significantly larger surface area in the small intestine and a longer small intestinal 
residence time are thought to aid the absorption of drug regardless of their degree of 
ionisation (Ashford, 2002b). 
 
1.1.4(f) Crystal form 
Polymorphs are crystal forms caused by differences in the packing and orientation of 
molecules under different crystallizing conditions. The physicochemical properties of 
these crystal forms such as density, solubility and melting point are influenced by the 
intermolecular forces present (Kwan et al., 1986). A metastable polymorph usually has 
a higher solubility and exhibits a greater dissolution rate than the corresponding stable 
polymorph. Consequently, the metastable polymorphic form of a poorly soluble drug 
may exhibit an increased bioavailability compared to the stable polymorphic form 
(Ashford, 2002b).  
 
However, the metastable polymorphs have the potential to convert to a more 
thermodynamically stable form leading to reduced solubility for the formulated product 
(Barich et al., 2005). One example is ritonavir, a protease inhibitor compound used to 
treat acquired immune deficiency syndrome (AIDS). This compound began production 
in a semisolid form and an oral liquid form. The appearance of a thermodynamically 
more stable polymorph with lower solubility led to a temporary withdrawal of the solid 
form from the market (Bauer et al., 2001).  
 
1.1.5 Dosage form factors 
1.1.5(a) Type of dosage form 
The type of dosage form and its method of preparation can influence the bioavailability. 
In general, the type of oral dosage form will influence the release of drug into solution 
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and hence the appearance of dissolved drug in the gastrointestinal tract. The 
bioavailability of a drug tends to be higher for liquid dosage forms like aqueous 
solutions and aqueous suspensions and lower for solid dosage forms such as capsules 
and tablets (Ashford, 2002b). 
 
1.1.5(b) Influence of excipients 
Most drugs intended for oral administration require formulation with excipients to allow 
for adequate absorption, to facilitate manufacturing of the product, to increase the 
stability of the formulation, for aesthetic reasons or for identification (Jackson et al., 
2000). Excipients have been classified according to the functions they perform in a 
formulation. These include disintegrating agents, diluents, lubricants, suspending 
agents, emulsifying agents, flavouring agents, colouring agents and chemical 
stabilizers (Ashford, 2002b).  
 
Excipients have traditionally been thought of as being inert, but experience has shown 
that they can interact with a drug to affect its absorption and bioavailability (Jackson et 
al., 2000). For instance, the potential influence of excipients on drug bioavailability has 
been shown by formation of poorly soluble, non-absorbable drug-excipient complexes 
between tetracyclines and dicalcium phosphate, amphetamine and sodium 
carboxymethycellulose, and phenobarbitone and polyethylene glycol (PEG) 4000 
(Ashford, 2002b). 
 
1.1.6 Methods to improve oral bioavailability 
Increasing the bioavailability of drugs administered orally remains a challenge in drug 
development. Many techniques including chemical modifications and formulation 
approaches have been employed to overcome the problems of poor and erratic oral 
bioavailability associated with drugs.  
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One of the techniques commonly used to overcome the problems of poor bioavailability 
is the prodrug approach, where the physicochemical properties of the drug are 
improved by bioreversible chemical alteration (Panchagnula and Thomas, 2000). The 
most common prodrug strategy involves the incorporation of a polar or ionisable moiety 
into the parent compound to improve aqueous solubility (Stella et al., 1998). Other 
approaches such as changing polymorphs and reducing melting points have been used 
to improve solubility of a drug (Ashford, 2002b).   
 
Besides, formulation approaches have been used to improve oral absorption of poorly 
soluble drugs. The most useful approach to improve solubility of an insoluble drug in 
water is to form water-soluble salts. If salt formation is not possible, a series of 
formulation approaches including pH adjustment, use of water-miscible cosolvents, 
surface-active agents, complexing agents and liposomes have been investigated 
(Panchagnula and Thomas, 2000). 
 
Complexing agents such as cyclodextrins are often used to increase the bioavailability 
of poorly water-soluble or unstable drugs. Complexation of water insoluble drugs 
usually involves the incorporation of the drug within the inner core of the complexing 
agent to improve solubility (Jackson et al., 2000). For example, the solubility of 
miconazole in water was increased upon complexation with cyclodextrins, leading to an 
increase in its dissolution rate and oral bioavailability (Tenjarla et al., 1998). 
 
Formulation of hydrophobic drugs into solid dispersions has also been employed to 
improve their dissolution and bioavailability. Solid dispersions consist of a water-soluble 
carrier and a hydrophobic drug dispersed in the carrier system. The hydrophilic carriers 
commonly used to formulate solid dispersions include PEG, polyvinyl pyrrolidone (PVP) 
and hydroxypropylmethyl cellulose (HPMC) (Jackson et al., 2000). PEG has been used 
to formulate solid dispersions with many types of drugs, including piroxicam 
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(Fernández et al., 1993), norfloxacin (Guyot et al., 1995) and ibuprofen (Ghosh et al., 
1998). In all cases, increases in dissolution and bioavailability of the drug were 
observed. 
 
On the other hand, adsorption of drug molecules onto surface of excipients with a small 
particle size or micronized excipients can reduce drug particle size and increase the 
surface area of drug available for dissolution. Both of these effects might increase 
dissolution and, as a result, bioavailability (Jackson et al., 2000). When indomethacin 
was formulated as an adsorbate with kaolin, an increase in dissolution was observed 
as compared to a simple mixture of the two components (Alsaidan et al., 1998).  
 
1.2 Adsorption of drugs 
1.2.1 Introduction 
Excipients are traditionally regarded as inert, and pharmacologically and toxicologically 
inactive (Pifferi et al., 1999). However, recent findings have shown that drugs and 
excipients can interact and they can have a tremendous impact on the bioavailability of 
a drug substance when added into a formulation. Most drug-excipient interactions 
affect the processes of disintegration and dissolution. These interactions also affect the 
physiological factors such as the pH of the microenvironment, the stability of a drug 
substance in the gastrointestinal tract and the permeability of gastrointestinal 
membranes to the drug (Jackson et al., 2000). 
 
A review of the literature on drug-excipient interactions shows that the mechanism of 
the interaction is often not clear. However, there are several well-documented 
mechanisms of drug-excipient interactions such as complexation, solid dispersions, 
chemical interaction and adsorption (Jackson et al., 2000). Adsorption is a term used to 
describe the process of accumulation of the atoms, ions, or molecules of a gas or other 
liquid at the surface of a solid (Marchal-Heussler and Barra, 2002). The adsorption 
 16 
which has generated most interest is that of a solute in solution on to a solid (Fell, 
2002).  
 
Adsorption is essentially a surface effect. Generally, there are two types of adsorption: 
physical adsorption, in which the adsorbate is bound to the surface through the weak 
van der Waals forces, and chemical adsorption, which involves the stronger valence 
forces (Florence and Attwood, 1988b). Physical adsorption usually involves small 
energy, with adsorption and desorption normally being rapid. Multilayer adsorption is 
possible, and desorption takes place without chemical change. On the other hand, 
chemical adsorption is restricted to the formation of a monolayer (Monkhouse and Lach, 
1972). However, both physical and chemical adsorptions may be involved in a 
particular adsorption process. This is the case with the adsorption of toxins in the 
stomach by attapulgite and kaolin (Florence and Attwood, 1988b).  
 
1.2.2 Adsorption isotherms 
The study of adsorption from solution generally involves the determination of an 
amount of solute adsorbed, x, by a given mass, m, of the adsorbent at constant 
temperature. Determinations are carried out at different equilibrium concentrations, C, 
to yield an adsorption isotherm (Fell, 2002).  
 
The isotherms obtained can generally be classified into four characteristic classes, 
based on the form of the initial part of the isotherm; and each class can be divided into 
subgroups in relation to the behaviour at higher concentrations. They are shown in 
Figure 1.1. The L (Langmuir) class is the most common and is characterized by an 
initial region which is concave to the concentration axis. The L2 isotherm reaches a 
plateau and further adsorption above this value gives the L3 isotherm, and if that 
reaches a second plateau it is designated as L4. The fifth L type reflects a special set 
of circumstances. They are observed with solutes that associate in solution and contain 
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highly surface-active impurities. For the S (slow) class, the initial slope is convex to the 
concentration axis, and this is frequently followed by a point of inflection leading to an 
S-shaped isotherm. The H (high affinity) class results from extremely strong adsorption 
at very low concentrations giving an apparent intercept on the ordinates while the C 
(constant partition) class has an initial linear portion which indicates constant partition 
of the solute between solution and adsorbent and this is observed with microporous 
adsorbents (Giles et al., 1960, 1974, Martin, 1993, Fell, 2002). 
 
 
 
Figure 1.1 Classification of isotherm shapes (adapted from Giles et al., 1960, 1974) 
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There have been many attempts to develop equations to fit the experimentally 
observed isotherms. Among the most widely used equations are the Langmuir 
adsorption isotherm, the Freundlich adsorption isotherm and the Brunauer, Emmett 
and Teller (BET) equations (Martin, 1993). However, in the current study, only the first 
two adsorption isotherms are used, and they are discussed in the following sections. 
 
1.2.2(a) Langmuir adsorption isotherm 
The equation was derived by assuming that only monolayer coverage was possible. 
The equation is usually written as 
    
x
m
 = 
abC
1 + bC
                                             (1.1) 
where x is the amount of solute adsorbed by a weight, m, of adsorbent. C is the 
concentration of the solution at equilibrium, and b and a are constants. Equation 1.1 
can be arranged into the linear form 
                    
C
(x/m)
 = 
1
ab
 + 
C
a
                                                      (1.2) 
Hence plotting C/(x/m) against C should give a straight line with a slope 1/a and 
intercept 1/ab (Florence and Attwood, 1988b, Martin, 1993, Fell, 2002). 
 
1.2.2(b) Freundlich adsorption isotherm 
The Freundlich equation is given as 
                      
x
m
 = kC1/n             (1.3) 
where n and k are constants for a particular system. Equation 1.3 can be written in a 
linear form by taking logarithms of both sides, giving 
                        log ( 
x
m
 ) = log k + (
1
n
) log C                                     (1.4) 
A plot of log (x/m) against log C should be linear, with an intercept of log k and slope of 
n-1. It is generally assumed that, for systems which obey this equation, adsorption 
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results in the formation of multilayer rather than a single monolayer (Florence and 
Attwood, 1988b, Fell, 2002). 
 
1.2.3 Factors affecting adsorption 
1.2.3(a) Solubility of the adsorbate 
Solubility is an important factor affecting adsorption. According to Lundelius’ rule, the 
extent of adsorption of a solute is inversely proportional to its solubility in the solvent 
from which adsorption occurs (Florence and Attwood, 1988b). In order for adsorption to 
occur, solute-solvent bonds must first be broken. Therefore, the greater the solubility, 
the stronger are these bonds and hence the smaller the extent of adsorption. Besides, 
it was shown that for most cases of adsorption from solution, the relative amount of 
solute removed is greater in dilute solutions (Fell, 2002).  
 
1.2.3(b) pH 
pH can affect adsorption in various manner, the most important from a pharmaceutical 
viewpoint being its effect on the ionisation and solubility of the adsorbate drug 
molecules. Generally, adsorption increases as the ionisation of the drug is suppressed 
and the extent of adsorption reaching a maximum when the drug is completely 
unionised (Florence and Attwood, 1988b).  
 
Normally, pH and solubility effects act in concert, since the unionised form of most 
drugs in aqueous solution has a low solubility. The solubility effect is usually the 
stronger among the two effects (Florence and Attwood, 1988b). In the adsorption of 
hyoscine and atropine on magnesium trisilicate, it was observed that hyoscine, 
although in its completely unionised form, was less strongly adsorbed than atropine, 
which at the pH of the experiment was 50 per cent ionised. The reason for this result is 
clear when the solubilities of the two bases are considered. Hyoscine base is freely 
soluble compared with atropine base. Even when it was 50 per cent ionised, atropine is 
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less soluble than hyoscine and consequently more strongly adsorbed (El-Masry and 
Khalil, 1974).  
 
1.2.3(c) Nature of the adsorbent 
The physicochemical nature of the adsorbent can have profound effects on the rate 
and capacity of adsorption. The most important property affecting adsorption is the 
surface area of the adsorbent. The extent of adsorption is proportional to the specific 
surface area (Florence and Attwood, 1988b).  Thus, an increased surface area, 
achieved by a reduction in particle size or the use of a porous material, will increase 
the extent of adsorption (Fell, 2002). 
 
Besides, adsorbent-adsorbate interactions may affect adsorption. These interactions 
are complex. Some particular adsorbents have affinities for particular adsorbates for a 
wide variety of reasons. The adsorbent clays such as bentonite, attapulgite and kaolin 
have cation-exchange sites on the surface. Such clays have strong affinities for 
protonated compounds which they adsorb by an ion-exchange process. Moreover, 
different parts of the surface of the same adsorbent may have different affinities for 
different types of adsorbents (Florence and Attwood, 1988b).  
 
1.2.3(d) Temperature 
Adsorption is generally an exothermic process. Therefore, an increase in temperature 
normally leads to a decrease in the amount adsorbed (Fell, 2002). The changes in 
enthalpy of adsorption are usually of the order of those for condensation or 
crystallisation. Thus, small variations in temperature tend not to alter the adsorption 
process to a significant extent (Florence and Attwood, 1988b).  
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1.2.4 Medical and pharmaceutical applications of adsorption 
1.2.4(a) Improving drug dissolution/bioavailability 
The adsorption of drug molecules onto the surface of excipients can reduce drug 
particle size and increase the surface area of drug available to the dissolution medium. 
Both of these effects might increase dissolution and, as a result, bioavailability 
(Jackson et al., 2000). Microcrystalline cellulose, polyvinylpyrrolidone and kaolin serve 
most often as adsorbents (Marchal-Heussler and Barra, 2002). 
 
The absorption of weak acid dicumarol in dogs was shown to be enhanced by 
magnesium hydroxide and magnesium oxide as a result of increased dissolution. This 
was attributed to the formation of a more readily absorbable dicumarol-magnesium 
chelate or to an increase in pH of the microenvironment caused by the addition of the 
excipients (Akers et al., 1973). In another study of indomethacin formulated as an 
absorbate with kaolin, an increase in dissolution was observed compared with a simple 
mixture of the two components. The authors suggested that, indomethacin crystallized 
on the surface of the adsorbent particles during the formation of adsorbate, leading to 
an increase in the surface area of drug available for dissolution (Alsaidan et al., 1998).  
 
1.2.4(b) Adsorption of noxious substances from the alimentary tract 
Adsorption onto finely divided solids has been utilized beneficially for a long time to 
remove bacterial toxins and for treatment of intoxication by drugs or chemicals (Nada 
et al., 1989). The commonly used oral antidotes for reducing the effects of poisoning 
include activated charcoal, magnesium oxide and tannic acid. Several drugs such as 
chlorpheniramine, propoxyphene hydrochloride, colchicines, diphenylhydantoin and 
acetylsalicylic acid are adsorbed effectively by activated charcoal. The interactions of 
drug molecules on the surface of the charcoal particles involved a non-polar, 
monolayer adsorption (Florence and Attwood, 1988b).  
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1.2.5 Adsorption problems in drug formulation 
Despite the advantages, adsorption may cause problems in formulation. Drugs and 
preservatives can be adsorbed by containers and undissolved materials in suspension, 
thereby reducing their effective concentrations (Fell, 2002). For example, the parabens 
may be adsorbed on to the solid materials present in a suspension, leading to a loss in 
antimicrobial activity (Allwood, 1982). The adsorption of insulin on to intravenous 
administration sets has been reported, as has the adsorption of phenylmercuric acetate, 
used as a preservative in eye drops, on to polyethylene containers (Aspinall et al., 
1980). 
 
1.3 Crospovidone 
1.3.1 Introduction 
Conventional tablets are formulated to release the active compounds within a relatively 
short interval in order to achieve optimal drug bioavailability. This is normally achieved 
by incorporating disintegrants to facilitate the break-up of granules and tablets into fine 
particles upon exposure to fluids in the gastrointestinal tract (Kottke and Rudnic, 2002).  
 
For several decades, starch has been one of the most widely used disintegrants in 
tablet manufacturing. However, starch has several drawbacks such as reduced 
effectiveness at high tablet compression forces and large amounts are needed to 
achieve the desired performance. Hence, alternative high-performance disintegrants, 
termed as super disintegrants, have been introduced into tablet technology. Super 
disintegrants permit low use levels and facilitate reliable disintegration (I.S.P., 2000a). 
Insoluble polyvinylpyrrolidone or cross-linked polyvinylpyrrolidone (crospovidone) are 
classified as super disintegrants.  
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1.3.2 Physical and chemical properties of crospovidone 
Crospovidone is a white, free flowing, high molecular weight, cross-linked polymer 
synthesized from the monomer vinylpyrrolidone by a popcorn polymerization technique 
using a catalyst (Kornblum and Stoopak, 1973, Shah and Augsburger, 2001). 
Crospovidone particles appear to consist of aggregates of smaller particles that are 
fused together. This aggregation gives crospovidone a spongy, highly porous 
appearance (Augsburger et al., 2001). The unique structure of crospovidone provides 
superior adsorptive capacity and exceptional swelling rate (I.S.P., 1999). The chemical 
structure of crospovidone is shown in Figure 1.2. 
 
 
Figure 1.2 Chemical structure of N-vinyl-2-pyrrolidone (I.S.P., 2000a) 
 
Crospovidone is completely insoluble in water and all other organic solvents due to its 
cross-linked structure. It does, however, swell extremely rapid in water which makes it 
one of the most widely used super disintegrant for solid dosage forms (I.S.P., 1999). 
An exact determination of the molecular weight has not been established because of 
the insolubility of the material (He and Kibbe, 2003). It is chemically inert and no 
chemical incompatibilities with drug actives have been recorded (I.S.P., 1999).  
 
Particle size distribution of crospovidone and its effect on the flow and swelling 
properties are important factors to consider for its use in pharmaceutical preparations 
(Bühler, 1999). Although the coarser grades of crospovidone were found to be more 
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efficient than those with finer particle sizes in tablet disintegration (Shah and 
Augsburger, 2001), a grade with relatively fine particle size of around 11 µm was 
selected for this present study. This is due to the high surface area of the finer 
crospovidone particles which provide superior adsorptive capacity (I.S.P., 1999).  
 
Crospovidone can form complexes with many molecules including a wide range of 
drugs as well as toxins. The complexation is reversible, involving the formation of weak 
hydrogen bonding or van der Waals forces rather than the covalent chemical bonds 
(I.S.P., 1999). However, complex formation of crospovidone is absent in alkaline 
medium. Therefore, its ability to reduce the absorption of toxins is controversial and this 
formed part of the aim of the present study. The degree of complexation also depends 
on the chemical structure of the drugs used. It has been shown that complexation may 
increase the rate and extent of drug dissolution (I.S.P., 2000a). 
 
1.3.3 Toxicological and safety profiles 
Crospovidone is used in oral pharmaceutical formulations and is generally regarded as 
a non-toxic and non-irritant material. Short-term animal toxicity studies showed that no 
adverse effect has been associated with crospovidone (He and Kibbe, 2003). The oral 
median lethal dose (LD50) in rats was more than 100 g/kg. It is not absorbed dermally 
and not a primary irritant or sensitizer. Long-term clinical studies showed that 
crospovidone products are not absorbed through the gastrointestinal tract due to its 
insolubility. It is essentially 100% excreted from the body. The Joint FAO/WHO Expert 
Committee for food additives has assigned crospovidone an Acceptable Daily Intake 
status of “Not Specified”, since it is not considered a health hazard (I.S.P., 1999, I.S.P., 
2000b).   
 
 
 
